Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms STREAM
- 28 Mar 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 28 Mar 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
- 04 Dec 2015 New trial record